Literature DB >> 831547

Catatonia: prediction of response to somatic treatments.

R Abrams, M A Taylor.   

Abstract

The authors investigated predictors of somatic treatment response in 55 patients with one or more of eight catatonic motor features. Responders more often had good prognostic signs, rapid or pressured speech, and diagnosable affective disorder or alcoholism. Nonresponders were younger at age of onset of first illness and were more frequently disoriented; they included all patients diagnosed as schizophrenic. The authors suggest that treatment response in catatonia is a function of primary diagnosis and that the syndrome is diagnostically nonspecific but occurs most often in patients with affective disorders.

Entities:  

Mesh:

Year:  1977        PMID: 831547     DOI: 10.1176/ajp.134.1.78

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  5 in total

Review 1.  Motor Abnormalities: From Neurodevelopmental to Neurodegenerative Through "Functional" (Neuro)Psychiatric Disorders.

Authors:  Victor Peralta; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

Review 2.  Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response.

Authors:  Federica Luchini; Pierpaolo Medda; Michela Giorgi Mariani; Mauro Mauri; Cristina Toni; Giulio Perugi
Journal:  World J Psychiatry       Date:  2015-06-22

3.  [Psychomotor disorders in psychiatric patients as a possible basis for new approaches in differential diagnosis and therapy. I. Results of initial studies in depressed and schizophrenic patients].

Authors:  W Günther; H Gruber
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1983

4.  Catatonia in autistic disorder: a sign of comorbidity or variable expression?

Authors:  G M Realmuto; G J August
Journal:  J Autism Dev Disord       Date:  1991-12

5.  The catatonic dilemma expanded.

Authors:  Heath R Penland; Natalie Weder; Rajesh R Tampi
Journal:  Ann Gen Psychiatry       Date:  2006-09-07       Impact factor: 3.455

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.